RecruitingPhase 2NCT07263139
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Studying Catecholaminergic polymorphic ventricular tachycardia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agiana Pharmaceuticals
- Principal Investigator
- Rizwan Hussain, MD PhDAgiana Pharmaceuticals AS
- Intervention
- AGP100(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- Department of Cardiology, Oslo University Hospital, Oslo, Norway
Collaborators
Link Medical Research AS · Viedoc Technologies AB · Vitas AS
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07263139 on ClinicalTrials.govOther trials for Catecholaminergic polymorphic ventricular tachycardia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07148089A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Solid Biosciences Inc.
- RECRUITINGPHASE2NCT06658899A Phase 2 Study of CRD-4730 in CPVTCardurion Pharmaceuticals, Inc.
- RECRUITINGNCT06661278Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited ArrhythmiasRoyal Brompton & Harefield NHS Foundation Trust
See all trials for Catecholaminergic polymorphic ventricular tachycardia →